Basel, 2018-06-28 - Novo Holdings A/S invests CHF 20 million in a seriesB extension financing of NBE-Therapeutics

NBE-Therapeutics has closed a CHF 20 million series B extension financing round bringing the total seriesB funding of NBE to CHF 40 million

Read more

Basel, 2018-03-05 - USPTO grants US patent for NBE-Therapeutics' core conjugation technology

NBE-Therapeutics has obtained a granted patent for the company's core SMAC-Technology in the United States

Read more

Basel, 2017-11-28 - NBE-Therapeutics appoints Dr. Nicole Onetto to its Board of Directors

Nicole Onetto, M.D., medical oncologist with strong track record in the development of targeted therapies in oncology joins NBE-Therapeutics' Board of Directors as independent Board member

Read more

Basel, 2017-05-15 - NBE-Therapeutics' publishes paper showcasing high potency of NBE's ADCs

Peer-reviewed paper describing NBE-Therapeutics' highly potent ADCs published in AACR journal Molecular Cancer Therapeutics

Read more

Basel, 2017-04-04 - NBE-Therapeutics expands Board by Appointment of Hans-Peter Gerber

Hans-Peter Gerber, internationally renowned expert in ADC development and previously CSO of Pfizer's Bioconjugates Division joins the Board of Directors of NBE-Therapeutics

Read more

next >